Clinical trials: Inflammation; Skin
Atopic Dermatitis, Atopic Dermatitis, Unspecified
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Trial name
- NCT05732454
- Testing
- etrasimod
- Where
- 74 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Moderate to Severe Atopic Dermatitis
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT03568162
- Testing
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3
- Where
- 83 sites in United States, Canada and 3 more
- Volunteers
- 462 people
- Sponsor
- Ichnos Sciences SA
Atopic Dermatitis
Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis
The purpose of this study is to compare the efficacy and cost effectiveness of Aquaphor Healing Ointment, Atopiclair and EpiCeram as a monotherapy in mild to moderate AD.
- Trial name
- NCT01093469
- Testing
- Atopiclair Nonsteroidal Cream, Aquaphor Healing Ointment, EpiCeram
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Wake Forest University Health Sciences
Atopic Dermatitis
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Heads Up (NCT03738397)
- Testing
- Upadacitinib, Dupilumab
- Where
- 159 sites in United States, Australia and 21 more
- Volunteers
- 673 people
- Sponsor
- AbbVie
Atopic Dermatitis
Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis
This study is designed to evaluate and compare the efficacy of 3% oregano extract ointment prepared in aqueous solution versus 1% hydrocortisone ointment, a standard treatment, in decreasing the inflammation associated with mild…
- Trial name
- NCT02289989
- Testing
- Oregano extract cream, Hydrocortisone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rutgers, The State University of New Jersey
Sjogren's Syndrome
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
Background: An autoimmune disease is one in which the immune system attacks a person's own body. Sjogren's syndrome (SS) is an autoimmune disease. It often involves multiple systems and organs of the body.
- Trial name
- NCT04496960
- Testing
- tofacitinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
- Trial name
- ECZTRA 2 (NCT03160885)
- Testing
- Tralokinumab
- Where
- 115 sites in United States, Australia and 7 more
- Volunteers
- 794 people
- Sponsor
- LEO Pharma
Atopic Dermatitis (AD)
Targeted Microbiome Transplant in Atopic Dermatitis
The purpose of this study is to examine the safety and effectiveness of a new therapy, commensal lotion containing infection fighting bacteria, on decreasing or eliminating the infection causing bacteria found on the skin of…
- Trial name
- NCT03151148
- Testing
- TMT Lotion
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hand Dermatosis
Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
The purpose of the study is to assess the safety, efficacy and tolerability of Clobetasol propionate foam in subjects with chronic dermatitis.
- Trial name
- NCT00828464
- Testing
- clobetasol propionate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stiefel, a GSK Company
Bacterial Infections, Diabetic Foot
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.
- Conditions
- Bacterial Infections, Diabetic Foot, Osteomyelitis
- Trial name
- NCT00366249
- Testing
- Tigecycline, Ertapenem
- Where
- 211 sites in United States, Argentina and 37 more
- Volunteers
- 1,061 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
The VIP-U Study is a clinical trial designed to investigate the effect of ustekinumab (Stelara) and placebo on reducing vascular inflammation and cardiometabolic risk biomarkers in patients with moderate to severe psoriasis.
- Trial name
- VIP-U (NCT02187172)
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Pennsylvania
Atopic Dermatitis
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine…
- Trial name
- BREEZE-AD4 (NCT03428100)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 103 sites in Austria, Belgium and 12 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Contact
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability…
- Trial name
- NCT00929981
- Testing
- Tablet Methylprednisolone (4 or 16 mg)
- Where
- 4 sites in India
- Volunteers
- 80 people
- Sponsor
- Pfizer
Healthy, Atopic Dermatitis
A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis
This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese…
- Trial name
- NCT03260595
- Testing
- Crisaborole ointment 2%, Vehicle
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer, Skin Reactions Secondary to Radiation Therapy
Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy.
- Trial name
- NCT02203565
- Testing
- Dakin's solution, radiation therapy, questionnaire administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Psoriatic Arthritis
The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated…
- Trial name
- NCT01818804
- Testing
- n-3PUFA, olive oil
- Where
- 2 sites in Denmark
- Volunteers
- 145 people
- Sponsor
- Aalborg University Hospital
Peristomal Skin Complication
Preliminary Evaluation of CASTLE Barrier Prototype UK
The purpose of this study is to provide preliminary assessment of the safety and performance of a novel barrier formulation (CASTLE) in a small population of subjects with irritated peristomal skin.
- Trial name
- NCT01530087
- Testing
- CASTLE barrier
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Hollister Incorporated
Atopic Dermatitis, Atopic Dermatitis Eczema
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
- Trial name
- NCT03667014
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Eczema, Egg Allergy
Promoting Tolerance to Peanut in High-Risk Children
This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema.
- Conditions
- Eczema, Egg Allergy, Food Allergy
- Trial name
- LEAP (NCT00329784)
- Testing
- Peanut Consumption Group
- Where
- United Kingdom
- Volunteers
- 640 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)